New gene therapy drug expected to hit market with head-spinning price tag
Share Now on:
The Food and Drug Administration is expected to approve a new gene therapy drug from pharmaceutical company Novartis by the end of May.
- Zolgensma is a treatment for spinal muscular atrophy
- Hundreds of children are born in the United States each year with the genetic, muscle-wasting disorder that kills many sufferers before they reach their second year
- Industry analysts expect the price for the single-treatment therapy to be from $1.5 million to $5 million
- Insurance companies might be reluctant to cover the drug
- Zolgensma represents a coming wave of gene therapy drugs that likely will carry whopping price tags
We’re here to help you navigate this changed world and economy.
Our mission at Marketplace is to raise the economic intelligence of the country. It’s a tough task, but it’s never been more important.
In the past year, we’ve seen record unemployment, stimulus bills, and reddit users influencing the stock market. Marketplace helps you understand it all, will fact-based, approachable, and unbiased reporting.
Generous support from listeners and readers is what powers our nonprofit news—and your donation today will help provide this essential service. For just $5/month, you can sustain independent journalism that keeps you and thousands of others informed.